Kiernan Aoife, Fahey Brian, Boland Fiona, Aherne Thomas
Royal College of Surgeons in Ireland, Dublin, Ireland; University of Edinburgh, Edinburgh, Scotland.
Royal College of Surgeons in Ireland, Dublin, Ireland.
J Vasc Surg Venous Lymphat Disord. 2023 May;11(3):648-656.e3. doi: 10.1016/j.jvsv.2022.12.068. Epub 2023 Feb 2.
Incompetent perforator veins are encountered frequently during ultrasound assessment of the venous system in chronic venous disease. Some studies have shown that concomitant treatment of truncal and perforator incompetence improves ulcer healing, yet a Cochrane review was unable to determine the potential benefits of perforator surgery in venous ulcer management due to poor quality evidence. This study aims to establish the exact role of concomitant treatment in patients with chronic venous disease.
A search of online databases including MEDLINE, Embase, and Cochrane was performed in March 2022. All studies comparing the outcomes of concomitant superficial venous plus perforator surgery with standard therapy were included. Variables assessed included ulcer healing, time to healing, and ulcer recurrence. Disease severity and quality of life, vein occlusion rates, number of incompetent perforator veins on duplex ultrasound post treatment, and reintervention and complication rates were also analyzed. Data were pooled using a random effects model.
Seven studies (872 limbs) were included for analysis. Included studies were of reasonable methodological quality. Ulcer healing rates were similar in each group (relative risk [RR], 1.07; 95% confidence interval [CI] 0.96-1.19; P = .23). Two studies reported no difference in mean time (days) to ulcer healing between groups (mean difference, -14.60; 95% CI, -34.57 to 5.38; P = .15; I = 0%; P = .56). Ulcer recurrence was significantly lower in the concomitant group (3.7% vs 44%) (RR, 0.21; 95% CI, 0.07- 0.65; P = .007; I = 43%; P = .17). Overall, there was no difference in disease severity measured at 12-month follow-up, with a weighted mean difference between groups of -0.88 (95% CI, -2.05 to 0.29; P = .14; I = 84%; P = .002). Quality of life was reported in only one study. The total number of perforator veins identified at follow-up duplex ultrasound was significantly lower in the concomitant group (22.4% vs 89%) compared with standard therapy (RR, 0.31; 95% CI, 0.19-0.53; P < .0001; I = 88%; P = .0002). There was no difference between groups for occlusion rates of treated great saphenous vein or incompetent perforators (RR, 2.22; 95% CI, 0.10-49.74; P = .61). Reported minor (RR, 0.98; 95% CI, 0.63-1.52; P = .92) and thrombotic complications (RR, 2.04; 95% CI, 0.59-6.99; P = .26) were similar between groups.
Concomitant truncal and perforator surgery is comparable to standard therapy in terms of ulcer healing, safety, and efficacy. Meta-analysis suggests that concomitant treatment could significantly reduce ulcer recurrence rates, but included studies were subject to some biases and short follow-up. Concomitant treatment may be considered to prevent recurrence rather than improve ulcer healing.
在慢性静脉疾病的静脉系统超声评估中,功能不全的穿支静脉经常被发现。一些研究表明,同时治疗主干静脉和穿支静脉功能不全可改善溃疡愈合,但Cochrane综述由于证据质量差,无法确定穿支静脉手术在静脉溃疡治疗中的潜在益处。本研究旨在确定同时治疗在慢性静脉疾病患者中的确切作用。
2022年3月对包括MEDLINE、Embase和Cochrane在内的在线数据库进行了检索。纳入所有比较同时进行浅静脉加穿支静脉手术与标准治疗结果的研究。评估的变量包括溃疡愈合、愈合时间和溃疡复发。还分析了疾病严重程度和生活质量、静脉闭塞率、治疗后双功超声检查发现的功能不全穿支静脉数量以及再次干预和并发症发生率。使用随机效应模型汇总数据。
纳入7项研究(872条肢体)进行分析。纳入研究的方法学质量合理。每组的溃疡愈合率相似(相对危险度[RR],1.07;95%置信区间[CI]0.96 - 1.19;P = 0.23)。两项研究报告两组之间溃疡愈合的平均时间(天)无差异(平均差,-14.60;95% CI,-34.57至5.38;P = 0.15;I² = 0%;P = 0.56)。同时治疗组的溃疡复发率显著更低(3.7%对44%)(RR,0.21;95% CI,0.07 - 0.65;P = 0.007;I² = 43%;P = 0.17)。总体而言,12个月随访时测量的疾病严重程度无差异,两组加权平均差为-0.88(95% CI,-2.05至0.29;P = 0.14;I² = 84%;P = 0.002)。仅一项研究报告了生活质量。与标准治疗相比,同时治疗组随访双功超声检查发现的穿支静脉总数显著更低(22.4%对89%)(RR,0.31;95% CI,0.19 - 0.53;P < 0.0001;I² = 88%;P = 0.0002)。治疗的大隐静脉或功能不全穿支静脉的闭塞率在两组之间无差异(RR,2.22;95% CI,0.10 - 49.74;P = 0.61)。报告的轻微并发症(RR,0.98;95% CI,0.63 - 1.52;P = 0.92)和血栓形成并发症(RR,2.04;95% CI,0.59 - 6.99;P = 0.26)在两组之间相似。
在溃疡愈合、安全性和有效性方面,同时进行主干静脉和穿支静脉手术与标准治疗相当。荟萃分析表明,同时治疗可显著降低溃疡复发率,但纳入研究存在一些偏倚且随访时间短。可考虑采用同时治疗来预防复发,而非改善溃疡愈合。